Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Shigematsu, Hideo ^a   Kawaguchi, Hidetoshi ^b   Nakamura, Yoshiaki ^b   Tanaka, Kimihiro ^b   Shiotani, Satoko ^b   Koga, Chinami ^b   Nishimura, Sumiko ^b   Taguchi, Kenichi ^b   Nishiyama, Kenichi ^b   Ohno, Shinji ^b  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; MEDROXYPROGESTERONE ACETATE; MITOMYCIN C; NAVELBINE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER CENTER; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CODING; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; RETROSPECTIVE STUDY; AGED; BREAST TUMOR; CARCINOMA; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; SURVIVAL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79953190470     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-118     Document Type: Article

References (38)

1. EBC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097.
2. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11):1081-1092. 10.1056/NEJMoa040331, 15014181.
3. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25(5):486-492. 10.1200/JCO.2006.08.8617, 17200148.
4. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1):45-53. 10.1016/S1470-2045(07)70385-6, 18083636.
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684. 10.1056/NEJMoa052122, 16236738.
6. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369(9555):29-36. 10.1016/S0140-6736(07)60028-2, 17208639.
7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354(8):809-820. 10.1056/NEJMoa053028, 16495393.
8. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009, 373(9673):1463-1479. 10.1016/S0140-6736(09)60316-0, 19394537.
9. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving?. Cancer 2004, 100(1):44-52. 10.1002/cncr.11859, 14692023.
10. Chia SK, Speers CH, D'Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'Reilly SE, Olivotto IA. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007, 110(5):973-979. 10.1002/cncr.22867, 17647245.
11. Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010, 119(3):621-631. 10.1007/s10549-009-0630-8, 19915976.
12. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2008, 26(30):4891-4898. 10.1200/JCO.2007.14.1168, 2736998, 18725649.
13. Bedard PL, Piccart-Gebhart MJ. Nonhormonal systemic therapy for advanced breast cancer: do the math!. J Natl Cancer Inst 2008, 100(24):1745-1747. 10.1093/jnci/djn433, 19066269.
14. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004, 22(16):3302-3308. 10.1200/JCO.2004.08.095, 15310773.
15. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010, 28(1):92-98. 10.1200/JCO.2008.19.9844, 2799236, 19933921.
16. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502. 10.1001/jama.295.21.2492, 16757721.
17. Maggie CU, Cheang D, Bajdik C, Leung S, Steven M, Stephen K C, Charles M P, andTorsten O N. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior PrognosticValue thanTriple-Negative Phenotype. Clin Cancer Res 2008, 14(5):1368-1374. 10.1158/1078-0432.CCR-07-1658, 18316557.
18. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28(20):3271-3277. 10.1200/JCO.2009.25.9820, 20498394.
19. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11(16):5678-5685. 10.1158/1078-0432.CCR-04-2421, 16115903.
20. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2329-2334. 10.1158/1078-0432.CCR-06-1109, 17438091.
21. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27(12):1999-2006. 10.1200/JCO.2008.19.6618, 19289619.
22. Gennatas C, Michalaki V, Carvounis E, Psychogios J, Poulakaki N, Katsiamis G, Voros D, Kouloulias V, Mouratidou D, Tsavaris N. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 2006, 92(1):13-17.
23. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005, 104(8):1742-1750. 10.1002/cncr.21359, 16149088.
24. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000, 18(22):3748-3757.
25. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000, 18(7):1399-1411.
26. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21(11):2101-2109. 10.1200/JCO.2003.04.194, 12775735.
27. Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L, Leonard RC. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005, 69(6):471-477. 10.1159/000090985, 16410685.
28. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792. 10.1056/NEJM200103153441101, 11248153.
29. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23(19):4265-4274. 10.1200/JCO.2005.04.173, 15911866.
30. Garcia-Saenz JA, Martin M, Puente J, Lopez-Tarruella S, Casado A, Moreno F, Grande E, Diaz-Rubio E. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005, 6(4):325-329. 10.3816/CBC.2005.n.035, 16277882.
31. Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008, 17(5):499-505. 10.1016/j.breast.2008.03.006, 18450443.
32. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003, 97(3):545-553. 10.1002/cncr.11083, 12548595.
33. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008, 113(10):2638-2645. 10.1002/cncr.23930, 2835546, 18833576.
34. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005, 23(15):3314-3321. 10.1200/JCO.2005.05.116, 15738536.
35. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005, 16(5):687-695. 10.1093/annonc/mdi162, 15802276.
36. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008, 26(15):2568-2581. 10.1200/JCO.2007.13.1748, 18487574.
37. Muss HB, Case LD, Richards F, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991, 325(19):1342-1348. 10.1056/NEJM199111073251904, 1922236.
38. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 2006, 8(6):R66. 10.1186/bcr1622, 1797029, 17129383.